Aliases & Classifications for Hiv-1

MalaCards integrated aliases for Hiv-1:

Name: Hiv-1 54 38
Hiv/aids 54 38 41 3
Aids 54 52 3
Aids, Delayed/rapid Progression to 54 13
Hiv1 Infection 54 38
Human Immunodeficiency Virus Type 1, Susceptibility to 29
Rapid Progression to Aids from Hiv1 Infection 54
Human Immunodeficiency Virus I Infection 69
Acquired Immunodeficiency Syndrome 69
Aids, Rapid Progression to 54
Aids, Slow Progression to 54
Hiv-Infection/aids 69
Hiv-1 Viremia 54
Hiv Type 1 54
Hiv1 54

Classifications:



External Ids:

OMIM 54 609423

Summaries for Hiv-1

MedlinePlus : 41 hiv stands for human immunodeficiency virus. it harms your immune system by destroying the white blood cells that fight infection. this puts you at risk for serious infections and certain cancers. aids stands for acquired immunodeficiency syndrome. it is the final stage of infection with hiv. not everyone with hiv develops aids. hiv most often spreads through unprotected sex with an infected person. it may also spread by sharing drug needles or through contact with the blood of an infected person. women can give it to their babies during pregnancy or childbirth. the first signs of hiv infection may be swollen glands and flu-like symptoms. these may come and go within two to four weeks. severe symptoms may not appear until months or years later. a blood test can tell if you have hiv infection. your health care provider can do the test, or you can use a home testing kit. or to find free testing sites, call the national referral hotline at 1-800-cdc-info (1-800-232-4636 in english and en español; 1-888-232-6348 - tty). there is no cure, but there are many medicines that fight hiv infection and lower the risk of infecting others. people who get early treatment can live with the disease for a long time.

MalaCards based summary : Hiv-1, also known as hiv/aids, is related to pulmonary tuberculosis and rheumatoid arthritis, and has symptoms including fever and pruritus. An important gene associated with Hiv-1 is KIR3DL1 (Killer Cell Immunoglobulin Like Receptor, Three Ig Domains And Long Cytoplasmic Tail 1), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Dolutegravir and Abacavir have been mentioned in the context of this disorder. Affiliated tissues include t cells, testes and monocytes, and related phenotypes are hematopoietic system and immune system

CDC : 3 Help

OMIM : 54
The pathogenesis of HIV infection and the progression from infection to AIDS vary significantly between exposed individuals. Infection occurs after the virus, which has macrophage (M)- and T lymphocyte (T)-tropic strains and more than 12 subtypes, survives an array of nonspecific, nongenetic environmental and host factors. (609423)

Related Diseases for Hiv-1

Diseases related to Hiv-1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 304)
id Related Disease Score Top Affiliating Genes
1 pulmonary tuberculosis 31.2 CCL2 CD209 IFNG
2 rheumatoid arthritis 30.7 CCL2 CCL3 CCR2 CXCL12 IFNG IL10
3 pulmonary embolism 30.5 CCL2 IFNG IL10
4 malaria 29.2 CCL11 CCL2 CCL3 IFNG IL10
5 aids - neurological complications 12.0
6 heart sarcoma 11.4 APOBEC3G CCL3 CCR2 CCR5 CD4 CXCL12
7 acral lentiginous melanoma 11.3 CCL3 CCR2 CCR5 CD4 IFNG IL10
8 uterine corpus epithelioid leiomyosarcoma 11.3 CCR5 CXCL12 CXCR4 IFNG IL10
9 ischemic optic neuropathy 11.3 CXCL12 CXCR4 IL10
10 progressive multifocal leukoencephalopathy 11.3
11 chronic cervicitis 11.3 CCR5 CXCL12 CXCR4
12 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids 11.3 CD4 IFNG IL10
13 oropharyngeal cancer, childhood 11.3 CCL3 CCR5 IFNG IL10
14 myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1 11.3 CCR2 CCR5 IFNG
15 progressive relapsing multiple sclerosis 11.3 CCR2 CCR5 IL10
16 hepadnavirus infection 11.3 CD209 IFNG IL10
17 detrusor sphincter dyssynergia 11.2 CCL2 CCR5 IFNG IL10
18 hypervitaminosis d 11.2 CCR5 IFNG IL10
19 acute necrotizing encephalopathy type 1 11.2 CXCR4 HLA-C IFNG
20 benign eccrine breast spiradenoma 11.2 CD209 IFNG IL10
21 advanced sleep phase syndrome, familial, 1 11.2 CCL2 CCL3 CCR5 IFNG IL10
22 hyperpigmentation of eyelid 11.2 CCL2 CCL3 IFNG IL10
23 orbital osteomyelitis 11.2 HLA-C IFNG IL10
24 eye accommodation disease 11.2 IFNG IL10
25 causalgia 11.2 CCL2 CCL3 IFNG IL10
26 uterus interstitial leiomyoma 11.1 CCL3 IFNG IL10
27 askin's tumor 11.1 CCL2 IFNG IL10
28 renal tubular acidosis 11.1 CCL2 CCR5 IFNG
29 benign infantile focal epilepsy with midline spikes and wave during sleep 11.1 CCL3 CCR5
30 mesenchymal cell neoplasm 11.1 CCL2 IFNG IL10
31 cockayne syndrome 11.1 CCL3 IFNG IL10
32 scabies 11.1 CCL2 IFNG IL10
33 neonatal jaundice 11.1 CCL2 IFNG IL10
34 interval angle-closure glaucoma 11.0 CCL2 CCR2
35 vulva fibroepithelial polyp 11.0 CCL2 IFNG IL10
36 inflammatory bowel disease 3 11.0 CCL2 CCL3 IFNG
37 myocardial infarction 11.0 CCL2 CCR5 CXCL12 CXCR4 IL10
38 esophageal candidiasis 11.0 CCL2 IFNG IL10
39 erythema multiforme 10.9 CCR5 CD209 IL10 TLR3
40 carotid artery dissection 10.9 CCL3 CCR5 CD209 CD4 CXCR4 IFNG
41 liver leiomyoma 10.9 CCR5 IL10 TLR3
42 dentinogenesis imperfecta 10.9 CD209 IFNG IL10 TLR3
43 macroglobulinemia, waldenstrom 1 10.8 CCR5 IFNG IL10
44 aspartylglucosaminuria 10.8 CD209 IFNG IL10
45 otomycosis 10.8 CCL3L1 CD209
46 bulbospinal polio 10.8 CCL3 IFNG TLR3
47 diabetes mellitus, insulin-dependent, 22 10.8 CCR5 CD209 TLR3
48 lower urinary tract calculus 10.8 CCL2 CCR5 CD209 TLR3
49 streptococcal meningitis 10.8 CCL2 CX3CR1 TLR3
50 duodenal somatostatinoma 10.8 CCL3 CCR5 CXCR1

Graphical network of the top 20 diseases related to Hiv-1:



Diseases related to Hiv-1

Symptoms & Phenotypes for Hiv-1

Clinical features from OMIM:

609423

UMLS symptoms related to Hiv-1:


fever, pruritus

MGI Mouse Phenotypes related to Hiv-1:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.13 CCL11 CCR2 CCR5 CD4 CX3CR1 CXCL12
2 immune system MP:0005387 10.1 TLR3 CCL11 CCL2 CCR2 CCR5 CD4
3 digestive/alimentary MP:0005381 9.97 IL4R CCR2 CCR5 CD4 CX3CR1 CXCR4
4 neoplasm MP:0002006 9.7 CCR2 CCR5 CXCR4 HCK IFNG IL10
5 no phenotypic analysis MP:0003012 9.5 CCR2 CCR5 CD4 CX3CR1 CXCL12 IFNG
6 respiratory system MP:0005388 9.23 CCL11 CCR2 CXCR4 HCK IFNG IL10

Drugs & Therapeutics for Hiv-1

Drugs for Hiv-1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 548)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1 Dolutegravir Approved Phase 4,Phase 3,Phase 2,Phase 1 1051375-16-6 54726191
2
Abacavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 136470-78-5 65140 441300
3
Darunavir Approved Phase 4,Phase 3,Phase 2,Phase 1 635728-49-3, 206361-99-1 213039
4
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 143491-57-0 60877
5
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 134678-17-4 60825
6
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 155213-67-5 392622
7
Maraviroc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 376348-65-1 3002977
8
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
9
Mycophenolic acid Approved Phase 4 24280-93-1 446541
10
Zidovudine Approved Phase 4,Phase 3,Phase 2,Phase 1 30516-87-1 35370
11
Efavirenz Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 154598-52-4 64139
12
Rilpivirine Approved Phase 4,Phase 3,Phase 2,Phase 1 500287-72-9
13
Lopinavir Approved Phase 4,Phase 3,Phase 2,Phase 1 192725-17-0 92727
14
Cobicistat Approved Phase 4,Phase 3,Phase 2,Phase 1 1004316-88-4
15
Didanosine Approved Phase 4,Phase 3,Phase 2,Phase 1 69655-05-6 50599
16
Nelfinavir Approved Phase 4,Phase 3,Phase 2,Phase 1 159989-64-7 64143
17
Stavudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 3056-17-5 18283
18
Amprenavir Approved Phase 4,Phase 3,Phase 2,Phase 1 161814-49-9 65016
19
Rifabutin Approved Phase 4,Phase 2,Phase 1 72559-06-9 6323490
20
Nevirapine Approved Phase 4,Phase 3,Phase 2,Phase 1 129618-40-2 4463
21
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
22
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1 36791-04-5 37542
23
Enfuvirtide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 159519-65-0 16130199
24
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 198153-51-4 5360545
25
Fosamprenavir Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 226700-79-4 131536
26
Indinavir Approved Phase 4,Phase 3,Phase 2,Phase 1 150378-17-9 5362440
27
Rifampin Approved Phase 4,Phase 3,Phase 2,Phase 1 13292-46-1 5458213 5381226
28
Tipranavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174484-41-4 65027
29
Guaifenesin Approved, Vet_approved Phase 4,Phase 3,Phase 1 93-14-1 3516
30
Methadone Approved Phase 4,Phase 1 76-99-3 4095
31
Etravirine Approved Phase 4,Phase 3,Phase 2,Phase 1 269055-15-4 193962
32
Atovaquone Approved Phase 4 95233-18-4 74989
33
Proguanil Approved Phase 4 500-92-5 4923
34
Saquinavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 127779-20-8 60787
35
Losartan Approved Phase 4,Phase 2 114798-26-4 3961
36
Benzocaine Approved Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
37
Delavirdine Approved Phase 4,Phase 3,Phase 2 136817-59-9 5625
38
Zalcitabine Approved Phase 4,Phase 2,Phase 3 7481-89-2 24066
39
Hydroxyurea Approved Phase 4,Phase 2,Phase 1 127-07-1 3657
40
Sorbitol Approved Phase 4 50-70-4 5780
41
Bleomycin Approved Phase 4,Phase 3 11056-06-7 5360373
42
Doxorubicin Approved, Investigational Phase 4,Phase 2 23214-92-8 31703
43
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2 2068-78-2, 57-22-7 5978
44
Prednisone Approved, Vet_approved Phase 4,Phase 2 53-03-2 5865
45
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 52485-79-7 40400 644073
46
Ethambutol Approved Phase 4,Phase 2,Phase 3 74-55-5 3279 14052
47
Isoniazid Approved Phase 4,Phase 2,Phase 3,Phase 1 54-85-3 3767
48
Pyrazinamide Approved Phase 4,Phase 2,Phase 3 98-96-4 1046
49
Peginterferon alfa-2b Approved Phase 4,Phase 3,Phase 1,Phase 2 99210-65-8, 215647-85-1
50
Everolimus Approved Phase 4,Phase 1,Phase 2 159351-69-6 6442177

Interventional clinical trials:

(show top 50) (show all 1993)

id Name Status NCT ID Phase Drugs
1 A Comparison of Virco®TYPE HIV-1 Testing Versus Expert Interpretation of Genotypic Results for Control of HIV-1 Replication Unknown status NCT00840762 Phase 4
2 Impact of Starting a Dolutegravir-based Regimen on HIV-1 Proviral DNA Reservoir Of Treatment Naïve and Experienced Patients Unknown status NCT02370979 Phase 4
3 Evaluation of the Efficacy and Safety Between Two Antiretroviral Regimens, in HIV-1-infected Treatment-naïve Subjects With Low CD4 Counts Unknown status NCT01928407 Phase 4 DARUNAVIR;ATAZANAVIR
4 Effect of Maraviroc (MCV) on the Immunological Recovery of HIV-1 Discordant Patients With CD4 Lymphocyte Counts Below 200 Cells/mm3 Unknown status NCT01235013 Phase 4 Maraviroc
5 Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients Unknown status NCT01013987 Phase 4 maraviroc;Raltegravir;Darunavir/ritonavir
6 Effects of Mycophenolate Mofetil (MMF) on Surrogate Markers for Cardiovascular Disease in HIV-1 Infected Patients Unknown status NCT00247494 Phase 4 mycophenol mofetil (MMF, Cellcept®) 500 mg BID
7 Efficacy and Safety of Raltegravir (RAL) in Treatment-experienced HIV-1 Infected Adult Chinese Patients Unknown status NCT01201239 Phase 4 raltegravir
8 Safety and Immune Response to Adjuvanted A(H1N1)v Influenza Vaccine in HIV-1 Infected and Immunosuppressed Adult Patients Unknown status NCT01017172 Phase 4
9 A Pilot Study of Triple NtRTI/NsRTI Therapy in Antiretroviral Naive HIV-1 Infected Patients Unknown status NCT00199121 Phase 4 Zidovudine (drug)
10 Switching From Efavirenz/Atripla to Rilpivirine Among Patients With Neurocognitive or Neuropsychological Side Effects Unknown status NCT02042001 Phase 4 Immediate switch to TDF/FTC/RPV;Switch to TDF/FTC/RPV after 12 weeks
11 Mycophenolate Mofetil in Antiretroviral Naïve Patients 2 (MAN2 Study) Unknown status NCT00120419 Phase 4 mycophenol mofetil (MMF, Cellcept®) 500 mg BID
12 PI Vs. NNRTI Based Therapy for HIV Advanced Disease Unknown status NCT00162643 Phase 4 zidovudine+lamivudine+lopinavir/ritonavir;zidovudine + lamivudine + efavirenz
13 Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects Unknown status NCT02404233 Phase 4 darunavir/cobicistat;rilpivirine
14 Treatment With Nelfinavir or Efavirenz of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs Unknown status NCT00005000 Phase 4 Nelfinavir mesylate;Efavirenz;Lamivudine;Keyhole-Limpet Hemocyanin;Stavudine;Zidovudine;Didanosine
15 Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment Unknown status NCT00005017 Phase 4 Ritonavir;Abacavir sulfate;Amprenavir;Efavirenz;Lamivudine;Stavudine
16 Safety and Effectiveness of TRIZIVIR (Abacavir/Lamivudine/Zidovudine) With Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs Unknown status NCT00011895 Phase 4 Abacavir sulfate, Lamivudine and Zidovudine;Efavirenz
17 Protease Inhibitor Monotherapy Versus Ongoing Triple-therapy in the Long Term Management of HIV Infection (PIVOT) Unknown status NCT01230580 Phase 4 Protease Inhibitor;Standard-of-care Antiretroviral therapy
18 SHARE: Simple HAART With Abacavir, Reyataz, and Epivir Unknown status NCT00426296 Phase 4 atazanavir (Reyataz);ritonavir (Norvir)
19 Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected Patients Unknown status NCT01059422 Phase 4 Raltegravir; Abacavir/Lamivudine
20 MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS) Unknown status NCT00122226 Phase 4 Lopinavir/ritonavir + zidovudine + lamivudine;Lopinavir/ritonavir + nevirapine
21 Computerized Counseling to Promote Positive Prevention and HIV Health in Kenya Unknown status NCT01015989 Phase 4
22 Efavirenz to Dolutegravir Switch in Patients With CNS Toxicity Unknown status NCT02285374 Phase 4 Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir
23 Maraviroc Abacavir STudy - Effect on Endothelial Recovery Unknown status NCT01389063 Phase 4 Maraviroc
24 Efficacy of PTX+IFN Alpha+ RBV on Hepatitis C Virus Coinfected HIV Patients Unknown status NCT02008214 Phase 4 Pentoxifylline;Placebo
25 Simplification From Protease Inhibitors to Raltegravir Unknown status NCT00941083 Phase 4 Raltegravir (Use RAL as a simplification strategy);Raltegravir (Use RAL as a simplification strategy);Raltegravir (Use RAL as a simplification strategy)
26 Once Daily 3TC, Efavirenz and ddI for HIV Infection Unknown status NCT00214435 Phase 4 once daily minimum 3-drug regimen of anti-retroviral medications
27 Early Access to Low-dose Ritonavir (TMC114/r) and Other Antiretrovirals (ARVs) for Treatment-naive or Early Treatment Experienced in HIV-1 Patients Completed NCT01702090 Phase 4 TMC114/ritonavir
28 Evolution of Plasma Lipid Profile in Patients With HIV1 Who Change Atripla to Eviplera Compared to Continue With Atripla Completed NCT02547844 Phase 4 efavirenz + emtricitabina + tenofovir;rilpivirina + emtricitabina + tenofovir
29 Valacyclovir vs. Acyclovir as HSV-2 Suppressive Therapy: Effect on Plasma HIV-1 Levels Among HIV-1/HSV-2 Co-infected Persons Completed NCT01026454 Phase 4 acyclovir;valacyclovir
30 Peripheral Body Fat Distribution After Switching Zidovudine and Lamivudine to Truvada Completed NCT00324649 Phase 4 Truvada;Zidovudine/lamivudine
31 Compare the Efficacy and Safety of Raltegravir Versus Efavirenz Combination Therapy in Treatment-naïve HIV-1 Patients Completed NCT01989910 Phase 4 Raltegravir;Efavirenz
32 Tenofovir DF (Disoproxil Fumarate) in Combination With Emtricitabine in HIV-1 Patients Completed NCT00106379 Phase 4 Truvada (tenofovir DF + emtricitabine);Emtriva (emtricitabine);Viread (tenofovir DF)
33 HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy in Spain Completed NCT00685191 Phase 4 Salvage antiretroviral therapy including raltegravir
34 Study to Compare the Virologic Efficacy in Cerebrospinal Fluid (CSF) and Neurocognitive State in Patients Infected by HIV-1 Long-term Treatment (> 3 Years) With Lopinavir / Ritonavir Monotherapy Completed NCT01116817 Phase 4
35 Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1—Infected Patients Completed NCT01332227 Phase 4 Atazanavir;Ritonavir (heat-stable);Raltegravir;Tenofovir/Emtricitabine
36 BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1. Completed NCT00326963 Phase 4 Background ARVs;PI;enfuvirtide [Fuzeon]
37 Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults Completed NCT02246998 Phase 4 STB;TVD;ATR;RTV;ATV;ABC/3TC;Iohexol
38 Single Tablet Regimen (STR) Simplification Study for HIV-1 Infected Patients Completed NCT00365612 Phase 4 Efavirenz (EFV), Emtricitabine (FTC), Tenofovir DF (TDF)
39 Prospective Epidemiological Study Of The Prevalence Of HLAB*5701 In HIV-1 Infected Patients Completed NCT00441688 Phase 4 GI265235
40 A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE) Completed NCT01102972 Phase 4 Reyataz + Norvir + Truvada;Reyataz + Epzicom
41 ROCKET II - Randomized Open Label Switch for Cholesterol Elevation on Kivexa + Kaletra Evaluation Trial Completed NCT00772902 Phase 4 Truvada + Kaletra;Kivexa + Kaletra
42 Metabolic Effects of Atazanavir/Ritonavir Versus Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine in naïve HIV-1 Infected Patients Completed NCT01274780 Phase 4 Darunavir / Ritonavir + Tenofovir / Emtricitabine;Atazanavir / Ritonavir + Tenofovir / Emtricitabine
43 Safety and Efficacy Study of Switching From Epzicom to Truvada Completed NCT00724711 Phase 4 emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF);abacavir (ABC)/lamivudine (3TC)
44 Maraviroc in Immunological Non-Responder (INR) HIV-1-infected Subjects Completed NCT00884858 Phase 4 Maraviroc
45 ONCE - Only Nocturnal Combination Evaluation of Antiretroviral-Experienced HIV 1 Infected Subjects Switching to Atripla Completed NCT00615745 Phase 4 Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg
46 Induction and Expansion of T Cell Repertoire Using Growth Hormone and Vaccination in HIV-1 Infected Patients Completed NCT00287677 Phase 4 HAART
47 Genotypic Tropism Testing In Proviral Dna To Guide CCR5 Antagonist Treatment In Subjects With Undetectable HIV-1 Viremia Completed NCT01378910 Phase 4 Unique
48 Immune Response to HPV Vaccine Among HIV-1-infected Subjects in Brazil Completed NCT02236234 Phase 4
49 Pharmacokinetic Study of Interaction Between Nevirapine and Methadone in HIV-1 Infected, Opioid-dependent Adults Completed NCT00273988 Phase 4 nevirapine
50 The CogNaive Study: Assessing Changes in Neurocognitive Function in Treatment Naïve HIV-1 Positive Subjects Completed NCT00540137 Phase 4 nevirapine;atazanavir/ritonavir

Search NIH Clinical Center for Hiv-1

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hiv-1 cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Hiv-1:
AGS-004, electroporated mature dendritic cells for HIV
Embryonic/Adult Cultured Cells Related to Hiv-1:
Maturated and electroporated dendritic cells PMIDs: 20636001

Genetic Tests for Hiv-1

Genetic tests related to Hiv-1:

id Genetic test Affiliating Genes
1 Human Immunodeficiency Virus Type 1, Susceptibility to 29

Anatomical Context for Hiv-1

MalaCards organs/tissues related to Hiv-1:

39
T Cells, Testes, Monocytes, Brain, Bone, Endothelial, B Cells

Publications for Hiv-1

Articles related to Hiv-1:

(show top 50) (show all 6393)
id Title Authors Year
1
TSPAN7, effector of actin nucleation required for dendritic cell-mediated transfer of HIV-1 to T cells. ( 28620031 )
2017
2
Does antiretroviral treatment change HIV-1 codon usage patterns in its genes: a preliminary bioinformatics study. ( 28086981 )
2017
3
Toll-Like Receptor 2 Ligation Enhances HIV-1 Replication in Activated CCR6+ CD4+ T Cells by Increasing Virus Entry and Establishing a More Permissive Environment to Infection. ( 27928019 )
2017
4
Haplotypes in CCR5-CCR2, CCL3 and CCL5 are associated with natural resistance to HIV-1 infection in a Colombian cohort. ( 28527291 )
2017
5
HIV-1 viral load measurement in venous blood and fingerprick blood using Abbott RealTime HIV-1 DBS assay. ( 28531553 )
2017
6
"Expand and Click": A New Method for Labeling HIV-1 Envelope Glycoproteins. ( 28525770 )
2017
7
CRISPR/Cas9-Mediated CCR5 Ablation in Human Hematopoietic Stem/Progenitor Cells Confers HIV-1 Resistance InA Vivo. ( 28527722 )
2017
8
Glycosylation and oligomeric state of envelope protein might influence HIV-1 virion capture by I+4I^7 integrin. ( 28577856 )
2017
9
Soil transmitted helminth infections are not associated with compromised antibody responses to previously administered measles and tetanus vaccines among HIV-1 infected, ART naA^ve Kenyan adults. ( 28924616 )
2017
10
The V3 Loop of HIV-1 Env Determines Viral Susceptibility to IFITM3 Impairment of Viral Infectivity. ( 28100616 )
2017
11
Sanger and Next-Generation Sequencing data for characterization of CTL epitopes in archived HIV-1 proviral DNA. ( 28934310 )
2017
12
HIV-1 Tat potently stabilises Mdm2 and enhances viral replication. ( 28468838 )
2017
13
Cytosine methylation by DNMT2 facilitates stability and survival of HIV-1 RNA in the host cell during infection. ( 28476776 )
2017
14
TCR Clonotype-specific Differences in Inhibitory Activity of HIV-1 Cytotoxic T Cell Clones is Not Mediated by TCR Alone. ( 28077649 )
2017
15
High-throughput Characterization of HIV-1 Reservoir Reactivation Using a Single-Cell-in-Droplet PCR Assay. ( 28529033 )
2017
16
Double-winged 3-Hydroxypyrimidine-2,4-diones: Potent and Selective Inhibition against HIV-1 RNase H with Significant Antiviral Activity. ( 28525279 )
2017
17
GRL-09510, a Unique P2-Crown-Tetrahydrofuranylurethane -Containing HIV-1 Protease Inhibitor, Maintains Its Favorable Antiviral Activity against Highly-Drug-Resistant HIV-1 Variants in vitro. ( 28947797 )
2017
18
An immunoregulatory role of dendritic cell-derived exosomes versus HIV-1 infection: take it easy but be warned. ( 28936456 )
2017
19
Siglec-1 initiates formation of the virus-containing compartment and enhances macrophage-to-T cell transmission of HIV-1. ( 28129379 )
2017
20
Non-Metabolic Role of PKM2 in Regulation of the HIV-1 LTR. ( 27249540 )
2017
21
Conformational dynamics of the frameshift stimulatory structure in HIV-1. ( 28522581 )
2017
22
Ritonavir and Topical Ocular Corticosteroid Induced Cushing's Syndrome in an Adolescent with HIV-1 Infection. ( 28060049 )
2017
23
A SAMHD1 mutation associated with Aicardi-Goutieres Syndrome uncouples the ability of SAMHD1 to restrict HIV-1 from its ability to downmodulate type I interferon in humans. ( 28229507 )
2017
24
Sensitive next generation sequencing method reveals deep genetic diversity of HIV-1 in the Democratic Republic of the Congo. ( 28077647 )
2017
25
Associations of CD4+ T-cell count, HIV-1 RNA viral load, and antiretroviral therapy with Kaposi sarcoma risk among HIV-infected persons in the United States and Canada. ( 28394855 )
2017
26
The interaction between HIV-1 Nef and adaptor protein-2 reduces Nef-mediated CD4(+) T cell apoptosis. ( 28577469 )
2017
27
Probing the HIV-1 NCp7 Nucleocapsid Protein with Site-Specific Gold(I)-Phosphine Complexes. ( 28937773 )
2017
28
USP7 deubiquitinase controls HIV-1 production by stabilizing Tat protein. ( 28280111 )
2017
29
Mycobacterium tuberculosis reactivates latent HIV-1 in T cells in vitro. ( 28949981 )
2017
30
Conserved residues within the HIV-1 Vpu transmembrane-proximal hinge region modulate BST2 binding and antagonism. ( 28288652 )
2017
31
A single gp120 residue can affect HIV-1 tropism in macaques. ( 28945790 )
2017
32
Structure based Virtual Screening toward the discovery of novel inhibitors for impeding the protein-protein interaction between HIV-1 integrase and human lens epithelium-derived growth factor (LEDGF/p75). ( 28948865 )
2017
33
Impact of HIV-1 Integrase L74F/V75I Mutations from a Clinical Isolate on Resistance to Second-Generation Integrase Strand Transfer Inhibitors. ( 28533248 )
2017
34
Identification of a tripartite interaction between the N-terminus of HIV-1 Vif and CBFI^ that is critical for Vif function. ( 28302150 )
2017
35
Virion-Associated Vpr Alleviates a Postintegration Block to HIV-1 Infection of Dendritic Cells. ( 28424288 )
2017
36
High prevalence of HIV-1 transmitted drug-resistance mutations from proviral DNA massively parallel sequencing data of therapy-naA^ve chronically infected Brazilian blood donors. ( 28953964 )
2017
37
Mapping Region of Human Restriction Factor APOBEC3H Critical for Interaction with HIV-1 Vif. ( 28336404 )
2017
38
Low Frequency of Acquired Isoniazid and Rifampicin Resistance in Rifampicin-Susceptible Pulmonary Tuberculosis in a Setting of High HIV-1 Infection and Tuberculosis Coprevalence. ( 28934422 )
2017
39
Adaptation of HIV-1 to cells with low expression of the CCR5 coreceptor. ( 28521215 )
2017
40
A G1-like state allows HIV-1 to bypass SAMHD1 restriction in macrophages. ( 28122869 )
2017
41
Correction: Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization. ( 28945784 )
2017
42
Reduced Frequency of Cells Latently Infected with Replication-Competent HIV-1 in Virally Suppressed Individuals Living in Rakai, Uganda. ( 28535179 )
2017
43
ADAR1 and PACT contribute to efficient translation of transcripts containing HIV-1 trans-activating response (TAR) element. ( 28167698 )
2017
44
Association of single nucleotide polymorphisms of APOBEC3G with susceptibility to HIV-1 infection and disease progression among men engaging in homosexual activity in northern China. ( 27730383 )
2017
45
Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors. ( 28951475 )
2017
46
I36Ta89T mutation in South African subtype C (C-SA) HIV-1 protease significantly alters protease-drug interactions. ( 28525359 )
2017
47
CD4 downregulation by the HIV-1 protein Nef reveals distinct roles for the I^1 and I^2 subunits of the AP-1 complex in protein trafficking. ( 27909244 )
2017
48
HIV controllers exhibit enhanced frequencies of MHC class II tetramer+ Gag-specific CD4+ T cells in chronic clade C HIV-1 infection. ( 28077659 )
2017
49
Cyclin F/FBXO1 Interacts with HIV-1 Viral Infectivity Factor (Vif) and Restricts Progeny Virion Infectivity by Ubiquitination and Proteasomal Degradation of Vif Protein through SCF(cyclin F) E3 Ligase Machinery. ( 28184007 )
2017
50
Clinical and Mucosal Immune Correlates of HIV-1 Semen Levels in Antiretroviral-Naive Men. ( 28534034 )
2017

Variations for Hiv-1

ClinVar genetic disease variations for Hiv-1:

6 (show all 13)
id Gene Variation Type Significance SNP ID Assembly Location
1 KIR3DL1 KIR3DS, KIR3DS +/- HLA-B Bw4-80ILE undetermined variant Pathogenic
2 CD209 CD209, -336A-G single nucleotide variant protective,risk factor
3 CCR5 NM_000579.3(CCR5): c.554_585del32 (p.Ser185Ilefs) deletion protective,risk factor rs333 GRCh37 Chromosome 3, 46414947: 46414978
4 CCR5 NM_000579.3(CCR5): c.303T> A (p.Cys101Ter) single nucleotide variant protective rs1800560 GRCh37 Chromosome 3, 46414696: 46414696
5 CCR5 NM_000579.3(CCR5): c.-301+246A> G single nucleotide variant protective rs1799987 GRCh37 Chromosome 3, 46411935: 46411935
6 CCR5 NM_000579.3(CCR5): c.180G> T (p.Arg60Ser) single nucleotide variant protective rs1800940 GRCh37 Chromosome 3, 46414573: 46414573
7 CCR2 NM_001123041.2(CCR2): c.190G> A (p.Val64Ile) single nucleotide variant protective rs1799864 GRCh37 Chromosome 3, 46399208: 46399208
8 CCL11 CCL11, -1385G-A single nucleotide variant protective
9 CXCL12 NM_000609.6(CXCL12): c.266+535G> A single nucleotide variant protective rs387906400 GRCh37 Chromosome 10, 44873550: 44873550
10 CCL2 CCL2, -2136A-T single nucleotide variant protective
11 CCL2 CCL2, 767C-G single nucleotide variant protective
12 IL10 IL10, -592C-A single nucleotide variant protective,risk factor
13 TLR3 NM_003265.2(TLR3): c.1234C> T (p.Leu412Phe) single nucleotide variant protective rs3775291 GRCh37 Chromosome 4, 187004074: 187004074

Copy number variations for Hiv-1 from CNVD:

7 (show all 23)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13736 1 1 247249719 Copy number HIV/AIDS
2 74031 13 1 114142980 Copy number HIV/AIDS
3 107129 17 1225928 31649829 Copy number CCL3L3 HIV/AIDS
4 107135 17 1225928 31649843 Copy number CCL3L1 HIV/AIDS
5 107136 17 1225928 31649843 Copy number CCL3L1 HIV/AIDS
6 107137 17 1225928 31649843 Copy number CCL3L1 HIV/AIDS
7 107145 17 1225928 31649843 Segmental duplicatio ns CCL3L1 HIV/AIDS
8 107159 17 1242109 31665953 Copy number CCL4L2 HIV/AIDS
9 110228 17 31562580 31665959 Copy number CCL4L1 HIV/AIDS
10 110279 17 31800000 38100000 Copy number CCL3L1 HIV/AIDS
11 110285 17 31800000 38100000 Copy number CCL4L1 HIV/AIDS
12 110286 17 31800000 38100000 Copy number CCL4L1 HIV/AIDS
13 110848 17 34522267 34625730 Copy number CCL3L1 HIV/AIDS
14 111275 17 35400000 35600000 Copy number CCL3L1 HIV/AIDS
15 112166 17 38100000 38400000 Copy number CCL3L1 HIV/AIDS
16 112167 17 38100000 38400000 Copy number CCL3L1 HIV/AIDS
17 112170 17 38100000 38400000 Loss CCL3L1 HIV/AIDS
18 179925 4 1 191273063 Copy number HIV/AIDS
19 209403 6 2614953 31491069 Copy number MICA HIV/AIDS
20 211349 6 32593131 32665540 Copy number HLA-DRB5 HIV/AIDS
21 212276 6 3674895 32665540 Copy number HLA-DRB1 HIV/AIDS
22 212425 6 3795995 32719407 Copy number HLA-DQA1 HIV/AIDS
23 212441 6 3813334 32742444 Copy number HLA-DQB1 HIV/AIDS

Expression for Hiv-1

LifeMap Discovery
Genes differentially expressed in tissues of Hiv-1 patients vs. healthy controls: 35 (show all 32)
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1 RBM25 RNA binding motif protein 25 Blood - 4.35 0.000
2 UBXN4 UBX domain protein 4 Blood - 4.25 0.000
3 LUC7L3 LUC7-like 3 pre-mRNA splicing factor Blood - 4.07 0.000
4 DKC1 dyskeratosis congenita 1, dyskerin Blood - 4.00 0.000
5 XIST X inactive specific transcript (non-protein coding) Lymph - 3.89 0.000
6 SYNCRIP synaptotagmin binding, cytoplasmic RNA interacting protein Blood - 3.79 0.000
7 AP3D1 adaptor-related protein complex 3, delta 1 subunit Blood - 3.77 0.000
8 SRRM2 serine/arginine repetitive matrix 2 Blood - 3.74 0.000
9 SON SON DNA binding protein Blood - 3.73 0.000
10 PTPRC protein tyrosine phosphatase, receptor type, C Blood - 3.67 0.000
11 NKTR natural killer cell triggering receptor Blood - 3.57 0.000
12 ESF1 ESF1 nucleolar pre-rRNA processing protein homolog Blood - 3.53 0.000
13 RBL2 retinoblastoma-like 2 Blood - 3.49 0.000
14 ADAM28 ADAM metallopeptidase domain 28 Blood - 3.48 0.000
15 PNISR PNN-interacting serine/arginine-rich protein Blood - 3.44 0.000
16 HSP90AA1 heat shock protein 90kDa alpha (cytosolic), class A member 1 Blood - 3.38 0.000
17 SCAF11 SR-related CTD-associated factor 11 Blood - 3.36 0.000
18 NBPF10 neuroblastoma breakpoint family, member 10 Blood - 3.35 0.000
19 PRRC2C proline-rich coiled-coil 2C Blood - 3.32 0.000
20 LRRN3 leucine rich repeat neuronal 3 Blood - 3.28 0.000
21 PPIG peptidylprolyl isomerase G (cyclophilin G) Blood - 3.27 0.000
22 IFI27 interferon, alpha-inducible protein 27 Blood + 3.25 0.000
23 TRIM23 tripartite motif containing 23 Blood - 3.23 0.000
24 ANKRD12 ankyrin repeat domain 12 Blood - 3.22 0.000
25 EIF1AY eukaryotic translation initiation factor 1A, Y-linked Lymph + 3.18 0.000
26 CHD4 chromodomain helicase DNA binding protein 4 Blood - 3.12 0.000
27 TNFAIP2 tumor necrosis factor, alpha-induced protein 2 Blood - 3.11 0.000
28 PTMA prothymosin, alpha Blood - 3.10 0.000
29 USO1 USO1 vesicle transport factor Blood - 3.09 0.000
30 ATRX alpha thalassemia/mental retardation syndrome X-linked Blood - 3.06 0.000
31 PRMT2 protein arginine methyltransferase 2 Blood - 3.04 0.000
32 TBL1X transducin (beta)-like 1X-linked Blood - 3.03 0.000
Search GEO for disease gene expression data for Hiv-1.

Pathways for Hiv-1

Pathways related to Hiv-1 according to GeneCards Suite gene sharing:

(show all 38)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.99 CCL11 CCL2 CCL3 CCL3L1 CCR2 CCR5
2
Show member pathways
13.85 CCL11 CCL2 CCL3 CCL3L1 CCR2 CCR5
3
Show member pathways
13.58 CCL11 CCL2 CCL3 CCL3L1 CCR2 CCR5
4
Show member pathways
13.54 CCL11 CCL2 CCL3 CCL3L1 CD4 CXCL12
5
Show member pathways
13.41 CCL11 CCL2 CCL3 CCL3L1 CCR2 CCR5
6
Show member pathways
13.32 CCL11 CCL2 CCL3 CCL3L1 CCR2 CCR5
7
Show member pathways
13.15 CCL11 CCL2 CCL3 CCL3L1 CCR2 CCR5
8
Show member pathways
13.13 CCL11 CCL2 CCL3 CCL3L1 CCR2 CCR5
9
Show member pathways
12.88 CCL2 CCL3 CCL3L1 IFNG IL10 TLR3
10
Show member pathways
12.87 CCL11 CD4 CXCL12 CXCR4 HLA-C IFNG
11
Show member pathways
12.76 CCL2 CD209 HLA-C IFNG TLR3
12 12.55 CCL2 CCR2 CXCL12 CXCR4 HCK IFNG
13
Show member pathways
12.49 CCL11 CCL2 CCL3 CCL3L1 CCR2 CCR5
14
Show member pathways
12.39 CCR5 CD4 IFNG IL10
15 12.39 CCR5 CXCR1 CXCR4 HLA-C
16 12.02 CD209 CD4 CX3CR1 IFNG IL10
17 12 CCL11 CCL2 IL10 IL4R
18
Show member pathways
11.99 CCL3 CCR5 CD4 IFNG
19
Show member pathways
11.96 CD4 IFNG IL10 TLR3
20
Show member pathways
11.93 CD4 IFNG IL4R TLR3
21 11.9 CCL2 CCL3 CCL3L1 CXCL12 IFNG
22 11.86 CCR2 CCR5 CXCL12 CXCR4 IFNG IL10
23 11.82 CCL3 CD4 IFNG IL10
24 11.79 CD209 CD4 CX3CR1 IFNG IL10
25 11.78 CCL3 CCL3L1 IFNG
26 11.78 CD4 CXCL12 CXCR4 HCK
27 11.69 CCL11 CCL2 CCL3 CCR2
28 11.64 CCL11 IL10 IL4R
29 11.61 CD4 CXCR4 IL10 IL4R
30 11.55 CCL11 CD4 IFNG IL10 IL4R
31 11.52 CCL2 IFNG IL10
32 11.51 CCL2 CCR2 IFNG
33 11.49 CCL2 CCL3 CCL3L1 CCR2 CCR5 IL10
34
Show member pathways
11.43 CCL3 IFNG IL10
35
Show member pathways
11.41 CCL11 CCL2 CCL3 CCL3L1 CCR2 CCR5
36 11.37 CCL2 CCR2 CX3CR1
37 11.29 CD4 IFNG IL10
38 11.24 CCL11 CCL2 CCL3 CCL3L1 CXCL12 IL10

GO Terms for Hiv-1

Cellular components related to Hiv-1 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.91 CCL11 CCL2 CCL3 CCL3L1 CD209 CXCL12
2 extracellular space GO:0005615 9.76 CCL11 CCL2 CCL3 CCL3L1 CXCL12 IFNG
3 cell surface GO:0009986 9.43 CCR5 CD209 CD4 CXCR4 HLA-C TLR3
4 external side of plasma membrane GO:0009897 9.02 CCR5 CD209 CD4 CXCL12 IFNG

Biological processes related to Hiv-1 according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
id Name GO ID Score Top Affiliating Genes
1 regulation of cell shape GO:0008360 9.97 CCL11 CCL2 CCL3 HCK
2 cellular response to lipopolysaccharide GO:0071222 9.97 CCL2 CCR5 CX3CR1 IFNG IL10
3 viral process GO:0016032 9.97 APOBEC3G CCR2 CCR5 CD209 CD4 CX3CR1
4 cellular response to tumor necrosis factor GO:0071356 9.96 CCL11 CCL2 CCL3 CCL3L1
5 response to virus GO:0009615 9.95 CCL11 CXCL12 CXCR4 IFNG TLR3
6 cellular calcium ion homeostasis GO:0006874 9.92 CCL11 CCL2 CCL3 CCR2 CXCL12
7 cellular response to interleukin-1 GO:0071347 9.91 CCL11 CCL2 CCL3 CCL3L1
8 chemotaxis GO:0006935 9.91 CCL11 CCL2 CCL3 CCR2 CCR5 CX3CR1
9 positive regulation of endothelial cell proliferation GO:0001938 9.9 CCL11 CCL2 CXCL12 IL10
10 inflammatory response GO:0006954 9.9 CCL11 CCL2 CCL3 CCL3L1 CCR2 CCR5
11 negative regulation of angiogenesis GO:0016525 9.89 CCL2 CCR2 CX3CR1
12 response to wounding GO:0009611 9.89 CCL2 CCR2 CX3CR1
13 interferon-gamma-mediated signaling pathway GO:0060333 9.88 HCK HLA-C IFNG
14 cell chemotaxis GO:0060326 9.88 CCL2 CCL3 CXCL12
15 cytokine-mediated signaling pathway GO:0019221 9.88 CCL2 CCR2 HCK IL4R
16 positive regulation of tumor necrosis factor production GO:0032760 9.88 CCL2 CCL3 IFNG TLR3
17 positive regulation of inflammatory response GO:0050729 9.87 CCL3 CCR2 TLR3
18 cellular defense response GO:0006968 9.86 CCR2 CCR5 CX3CR1
19 monocyte chemotaxis GO:0002548 9.86 CCL11 CCL2 CCL3 CCL3L1
20 calcium-mediated signaling GO:0019722 9.85 CCL3 CCR5 CXCR4
21 positive regulation of cell adhesion GO:0045785 9.85 CCL2 CXCL12 IFNG
22 antigen processing and presentation GO:0019882 9.85 CD209 HLA-C IFNG
23 lipopolysaccharide-mediated signaling pathway GO:0031663 9.83 CCL2 CCL3 HCK
24 neutrophil chemotaxis GO:0030593 9.83 CCL11 CCL2 CCL3 CCL3L1 IFNG
25 positive regulation of T cell activation GO:0050870 9.81 CCL2 CCR2 CD4
26 defense response to protozoan GO:0042832 9.81 IFNG IL10 IL4R
27 positive regulation of monocyte chemotaxis GO:0090026 9.8 CCL2 CCR2 CXCL12
28 lymphocyte chemotaxis GO:0048247 9.8 CCL11 CCL2 CCL3 CCL3L1
29 cellular response to interferon-gamma GO:0071346 9.8 CCL11 CCL2 CCL3 CCL3L1 TLR3
30 positive regulation of calcium ion import GO:0090280 9.78 CCL2 CCL3 CXCL12
31 macrophage chemotaxis GO:0048246 9.77 CCL2 CCL3 CX3CR1
32 immune response GO:0006955 9.73 CCL11 CCL2 CCL3 CCR2 CCR5 CD4
33 viral genome replication GO:0019079 9.72 CCL2 CD209
34 cellular homeostasis GO:0019725 9.72 CCL2 CCR2
35 positive regulation of chemokine biosynthetic process GO:0045080 9.71 IFNG TLR3
36 fusion of virus membrane with host plasma membrane GO:0019064 9.71 CCR5 CD4 CXCR4
37 response to cholesterol GO:0070723 9.7 CCL3 CCR5
38 chronic inflammatory response GO:0002544 9.7 CCL11 CCL2
39 eosinophil chemotaxis GO:0048245 9.7 CCL11 CCL3
40 signaling GO:0023052 9.7 CCL3 CCR5
41 positive regulation of MHC class II biosynthetic process GO:0045348 9.69 IFNG IL10
42 release of sequestered calcium ion into cytosol by sarcoplasmic reticulum GO:0014808 9.68 CCL3 CCR5
43 astrocyte cell migration GO:0043615 9.68 CCL2 CCL3
44 regulation of vascular endothelial growth factor production GO:0010574 9.67 CCL2 CCR2
45 dendritic cell chemotaxis GO:0002407 9.67 CCR2 CCR5 CXCR1 CXCR4
46 microglial cell activation involved in immune response GO:0002282 9.66